Exelixis Inc (EXEL) Return on Equity ROE from the second quarter 2026 to second quarter 2025 and annually, average high and low, overall ranking from Jul 03 2026 to Jul 04 2025 - CSIMarket
Return on Equity, Quarterly Results, Trends, Rankings, Statistics
What is ROE for Exelixis Inc in the second quarter 2026? Exelixis Inc achieved a return on average equity (ROE) of 93.62 % in its second quarter 2026, this is above EXEL's average return on equity of -12.52%. Exelixis Inc s equity during the 12 months ending in the second quarter 2026 are valued at $2 billion
While the company's net income was fading, Exelixis Inc was able to improve its ROE compared to the first quarter 2026.
Within the Biotechnology & Pharmaceuticals industry 2 other companies had a higher return on equity. While Return on equity, overall ranking has advanced in the quarter, so far to 105, from total ROE ranking in the first quarter 2026 at 110.
In a series of significant updates, Exelixis, Inc. has made waves in the biopharmaceutical landscape through a combination of legal victories, clinical collaborations, and promising clinical trial results. As the company continues to build on its cancer treatment portfolio, the implications of these developments could profoundly shape its future. Patent Litigation SuccessExelixis recently secured a critical victory in the ongoing patent litigation against MSN Laboratories. The U.S. District Court for the District of Delaware ruled in favor of Exelixis, upholding the validity of three key patents associated with its drug cabozantinib: U.S. Patents No. 11,091,439, 11,091,440, and 11,098,015. These patents are critical as they cover essential aspects of cabozantinib, including a crystalline salt and pharmaceutical compositions. The court s decision not only strengthens Exelixis s intellectual property rights but also safeguards its revenue potential. By reinforcing its patent protections, Exelixis can maintain its market exclusivity for cabozantinib, thereby mitigating the risk of generic competition that could lead to significant revenue loss. This outcome is vital for maintaining investor confidence and continuing to fund research and development initiatives.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
